HIGH-DOSE INACTIVATED INFLUENZA VACCINE IS ASSOCIATED WITH COST SAVINGS AND BETTER OUTCOMES COMPARED TO STANDARD-DOSE INACTIVATED INFLUENZA VACCINE IN SENIORS

被引：0
|
作者：
Chit, A. [1 ]
Becker, D. L. [2 ]
Diazgranados, C. [1 ]
Maschio, M. [3 ]
Yau, E. [1 ]
Drummond, M. [4 ]
机构：
[1] Sanofi Pasteur, Swiftwater, PA USA
[2] Optum, Burlington, ON, Canada
[3] OptumInsight, Burlington, ON, Canada
[4] Univ York, York YO10 5DD, N Yorkshire, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.1399
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN75
引用
收藏
页码：A240 / A240
页数：1
相关论文
共 50 条
  • [41] Cost Effectiveness of Influenza Vaccine for US Children Live Attenuated and Inactivated Influenza Vaccine
    Shim, Eunha
    Brown, Shawn T.
    DePasse, Jay
    Nowalk, Mary Patricia
    Raviotta, Jonathan M.
    Smith, Kenneth J.
    Zimmerman, Richard K.
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2016, 51 (03) : 309 - 317
  • [42] Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines
    DiazGranados, Carlos A.
    Robertson, Corwin A.
    Talbot, H. Keipp
    Landolfi, Victoria
    Dunning, Andrew J.
    Greenberg, David P.
    VACCINE, 2015, 33 (38) : 4988 - 4993
  • [43] Relative vaccine efficacy of high-dose versus standard-dose influenza vaccines in preventing probable influenza in a Medicare Fee-for-Service population
    Paudel, Misti
    Mahmud, Salah
    Buikema, Ami R.
    Korrer, Stephanie
    Van Voorhis, Damon
    Brekke, Lee
    Chit, Ayman
    VACCINE, 2020, 38 (29) : 4548 - 4556
  • [44] Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain
    Perez-Rubio, Alberto
    Flores, Roberto
    Aragon, Jesus Ruiz
    Sanchez, Javier
    Marquez-Pelaez, Sergio
    Alvarez, Piedad
    Muriel, Andres Osorio
    Mould-Quevedo, Joaquin
    VACCINES, 2025, 13 (03)
  • [45] Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations
    Yaron, Shlomit
    Yechezkel, Matan
    Yamin, Dan
    Razi, Talish
    Borochov, Ilya
    Shmueli, Erez
    Arbel, Ronen
    Netzer, Doron
    NPJ VACCINES, 2025, 10 (01)
  • [46] Randomized Controlled Trial of High-Dose Intradermal Versus Standard-Dose Intramuscular Influenza Vaccine in Organ Transplant Recipients
    Baluch, A.
    Humar, A.
    Eurich, D.
    Egli, A.
    Liacini, A.
    Hoschler, K.
    Campbell, P.
    Berka, N.
    Urschel, S.
    Wilson, L.
    Kumar, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (04) : 1026 - 1033
  • [47] Relative Vaccine Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among Veterans Health Administration Patients
    Young-Xu, Yinong
    Van Aalst, Robertus
    Mahmud, Salaheddin M.
    Rothman, Kenneth J.
    Snider, Julia Thornton
    Westreich, Daniel
    Mor, Vincent
    Gravenstein, Stefan
    Lee, Jason K. H.
    Thommes, Edward W.
    Decker, Michael D.
    Chit, Ayman
    JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (11): : 1718 - 1727
  • [48] Immunogenicity and reactogenicity of high- vs. standard-dose trivalent inactivated influenza vaccine in healthcare workers: a pilot randomized controlled trial
    Volling, C.
    Coleman, B. L.
    Katz, K.
    Simor, A. E.
    Muller, M.
    Powis, J.
    McElhaney, J.
    McGeer, A.
    CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (02) : 217 - 224
  • [49] Provider knowledge of trivalent inactivated and high-dose influenza vaccines
    Tewell, Chad
    Wright, Patty W.
    Talbot, H. Keipp
    VACCINE, 2014, 32 (46) : 6025 - 6028
  • [50] Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults
    Greenberg, David P.
    Robertson, Corwin A.
    Noss, Michael J.
    Blatter, Mark M.
    Biedenbender, Rex
    Decker, Michael D.
    VACCINE, 2013, 31 (05) : 770 - 776
12345